****

**ASCO Meeting 2024 Participation**

(For release after May 22nd)

2025 Conquer Cancer Career Development Award

Recipient: Bejamin Lu

**Breast Cancer—Metastatic**

Friday, May 30: Rapid Oral Abstract

2:45 – 4:15 PM

Panelist: Patricia LoRusso

Location: Hall D2

<https://meetings.asco.org/2025-asco-annual-meeting/16340?presentation=252873#252873>

**Dose optimization of PF-07248144, a first-in-class KAT6 inhibitor, in patients (pts) with ER+/HER2− metastatic breast cancer (mBC): Results from phase 1 study to support the recommended phase 3 dose (RP3D)**

Friday, May 30: Rapid Oral Abstract

3:51 – 3:57 PM

Presenter: Patricia LoRusso

Location: Hall D2 | Abstract 1020

<https://meetings.asco.org/2025-asco-annual-meeting/16340?presentation=252873#252873>

**Identification of differential epigenetic landscapes in subtypes of appendiceal cancer**

Saturday, May 31: Poster Session

9:00 AM – 12:00 PM

Location: Hall A | Abstract 4199 | Poster 489

Presenter: Luisa Ladel

<https://meetings.asco.org/2025-asco-annual-meeting/16360?presentation=249893#249893>

**Comparison of MET genomic alterations (GA) identified in colorectal cancer (CRC) vs gastric cancer (GCA)**

Saturday, May 31: Poster Session

9:00 AM – 12:00 PM

Location: Hall A | Abstract 3570 | Poster 239

Presenter: Faiza Yasin

<https://meetings.asco.org/2025-asco-annual-meeting/16357?presentation=244796#244796>

**Treatment discontinuation in desmoid tumors: Factors associated with better outcomes after sorafenib discontinuation**

Saturday, May 31: Poster Session

9:00 AM – 12:00 PM

Location: Hall A | Abstract 11562 | Poster 45

Presenter: Irvin Yi

<https://meetings.asco.org/2025-asco-annual-meeting/16405?presentation=247059#247059>

**Factors associated with decreased treatment intensity in patients with metastatic colon cancer: A real world analysis**

Saturday, May 31: Poster Session

9:00 AM – 12:00 PM

Location: Hall A | Abstract 11168| Poster 507

Presenter: Tendai Kwaramba

<https://meetings.asco.org/2025-asco-annual-meeting/16405?presentation=247059#247059>

**Impact of social determinants of health on mortality in diffuse large B-cell lymphoma (DLBCL) using real-world data**

Saturday, May 31: Poster Session

9:00 AM – 12:00 PM

Location: Hall A | Abstract 11097| Poster 436

Presenter: Maureen Canavan

<https://meetings.asco.org/2025-asco-annual-meeting/16405?presentation=247059#247059>

**Identification of differential epigenetic landscapes in subtypes of appendiceal cancer**

Saturday, May 31: Poster Session

9:00 AM – 12:00 PM

Location: Hall A | Abstract 4199 | Poster 489

Presenter: Luisa Ladel

<https://meetings.asco.org/2025-asco-annual-meeting/16360?presentation=249443#249443>

**Presentation of Awards and the Fellows of the American Society of Clinical Oncology (FASCO)**

Saturday, May 31: Opening Session

Location: Hall B1

11:15 – 11:30 AM

Presenter: Eric Winer

<https://meetings.asco.org/2025-asco-annual-meeting/16449?presentation=243416#243416>

**ASCO/AACR Joint Session: Lessons From Gene Therapy in Practice: Successes, Challenges, and How to Have Access for All**

Saturday, May 31: Education Session

Location: E450a

1:15 – 2:30 PM

Chair and Moderator: Patricia LoRusso

<https://meetings.asco.org/2025-asco-annual-meeting/16453?presentation=243478#243478>

**Association of circulating tumor DNA (ctDNA) variant allelic frequency (VAF) with outcomes on matched targeted therapies (TT) in advanced non-small cell lung cancer (aNSCLC)**

Saturday, May 31: Poster Session

1:30 – 4:30 PM

Location: Hall A | Abstract 8628 | Poster 108

Presenter: Amin Nassar

<https://meetings.asco.org/abstracts-presentations/251775>

**Clinical features associated with an exceptional response to immunotherapy in patients with metastatic non-small cell lung cancer (NSCLC)**

Saturday, May 31: Poster Session

1:30 – 4:30 PM

Location: Hall A | Abstract 8544 | Poster 24

Presenter: Yunan Nie

<https://meetings.asco.org/abstracts-presentations/251775>

**Impact of a novel oral medication delivery device on patient engagement and discontinuation in individuals receiving oral oncolytic medications**

Saturday, May 31: Poster Session

1:30 – 4:30 PM

Location: Hall A | Abstract 11063 | Poster 402

##### Presenter: Melissa Taylor

<https://meetings.asco.org/abstracts-presentations/251775>

**Use of targeted therapy in patients with advanced non-small cell lung cancer in response to broad genomic profiling**

Saturday, May 31: Poster Session

1:30 – 4:30 PM

Location: Hall A | Abstract 11155 | Poster 494

##### Presenter: Xiao Wang

<https://meetings.asco.org/abstracts-presentations/251775>

**Cost-effectiveness of ribociclib plus endocrine therapy in HR-positive, HER2-negative early breast cancer in the United States**

Saturday, May 31: Poster Session

1:30 – 4:30 PM

Location: Hall A | Abstract 11049 | Poster 388

##### Presenter: Kunal C Potnis

<https://meetings.asco.org/abstracts-presentations/251775>

**Industry promotion of oncology drugs with accelerated approval that failed confirmatory trials**

Saturday, May 31: Poster Session

1:30 – 4:30 PM

Location: Hall A | Abstract 11029 | Poster 368

##### Presenter: Maryam Mooghali

<https://meetings.asco.org/2025-asco-annual-meeting/16402?presentation=247359#247359>

**Publication and data sharing of completed NCI cooperative group trials**

Saturday, May 31: Poster Session

1:30 – 4:30 PM

Location: Hall A | Abstract 11023 | Poster 362

Presenter: Lauren N Cueto

<https://meetings.asco.org/2025-asco-annual-meeting/16402?presentation=247359#247359>

**Definitive radiation as a nonsurgical option after chemoimmunotherapy for stage III lung cancer**

Saturday, May 31: Poster Session

1:30 – 4:30 PM

Location: Hall A | Abstract 8072 | Poster 193

Presenter: Giorgio Caturegli

<https://meetings.asco.org/2025-asco-annual-meeting/16384?presentation=249071#249071>

**Genetics and family history in a diverse cohort of females with early-onset breast cancer**

Saturday, May 31: Poster Session

1:30 – 4:30 PM

Location: Hall A | Abstract 10613 | Poster 338

Presenter: Tanaya Shroff

<https://meetings.asco.org/2025-asco-annual-meeting/16399?presentation=251564#251564>

**Biomarkers in Kidney Cancer: Are We There Yet?**

Saturday, May 31: Clinical Science Symposium

4:30 – 6:00 PM

Location: Arie Crown Theater

Panelist: David Braun

<https://meetings.asco.org/2025-asco-annual-meeting/16506?presentation=246146#246146>

**Biomarkers in Kidney Cancer: Are We There Yet?**

Saturday, May 31: Clinical Science Symposium

4:30 – 6:00 PM

Location: Arie Crown Theater

Panelist: Renee Saliby

<https://meetings.asco.org/2025-asco-annual-meeting/16506?presentation=246146#246146>

**Redefining the Role of Chemotherapy in the Era of Targeted Therapies in Breast Cancer**

Saturday, May 31: Award Lecture

4:45 – 5:30 PM

Location: Hall B1

Chair and Moderator: Eric Winer

<https://meetings.asco.org/2025-asco-annual-meeting/16465?presentation=243112#243112>

**Redefining the Role of Chemotherapy in the Era of Targeted Therapies in Breast Cancer**

Saturday, May 31: Award Lecture

4:45 – 5:30 PM

Location: Hall B1

Award Recipient and Panelist: Ian Krop

<https://meetings.asco.org/2025-asco-annual-meeting/16465?presentation=243112#243112>

**An integrative analysis of circulating and tumor microenvironment (TME) determinants of patient response in the Checkmate 9ER (CM 9ER) trial of nivolumab and cabozantinib (NIVO+CABO) in advanced renal cell carcinoma (aRCC)**

Saturday, May 31: Clinical Science Symposium

5:06 – 5:18 PM

Location: Arie Crown Theater | Abstract 4511

Presenter: David Braun

<https://meetings.asco.org/2025-asco-annual-meeting/16506?presentation=246146#246146>

**Gut-associated checkpoint as a prognostic biomarker in metastatic renal cell carcinoma (mRCC): Results from a randomized first-line clinical trial**

Saturday, May 31: Clinical Science Symposium

5:18 – 5:30 PM

Location: Arie Crown Theater | Abstract 4512

Presenter: Renee Saliby

<https://meetings.asco.org/2025-asco-annual-meeting/16506?presentation=246146#246146>

**Highlights of the Day I: Head and Neck Cancer**

Sunday, June 1: Special Session

9:00 – 9:15 AM

Location: Hall D1

Presenter: Barbara Burtness

<https://meetings.asco.org/2025-asco-annual-meeting/16483?presentation=252858#252858>

**30 year trends in racial disparities for early stage lung cancer treatment**

Sunday, June 1: Poster Session

9:00 AM – 12:00 PM

Location: Hall A | Abstract 1599 | Poster Board 365

Presenter: Olivia Lynch

<https://meetings.asco.org/2025-asco-annual-meeting/16345?presentation=245420#245420>

**Risk and predictors of late second primary malignancies in long-term breast, prostate, colon, and rectal cancer survivors**

Sunday, June 1: Poster Session

9:00 AM – 12:00 PM

Location: Hall A | Abstract 1642 | Poster Board 408

Presenter: Tendai Kwaramba

<https://meetings.asco.org/2025-asco-annual-meeting/16345?presentation=245420#245420>

**Qualitative findings from providers and patients for planning implementation of screening clinical breast examination in Soweto, South Africa**

Sunday, June 1: Poster Session

9:00 AM – 12:00 PM

Location: Hall A | Abstract 1539 | Poster Board 292

Presenter: Daniel O’Neil

<https://meetings.asco.org/2025-asco-annual-meeting/16345?presentation=245420#245420>

**The impact of race on the association between structural racism and the quality of non-small cell lung cancer (NSCLC)**

Sunday, June 1: Poster Session

9:00 AM – 12:00 PM

Location: Hall A | Abstract 1598 | Poster Board 364

Presenter: Jacquelyne Gaddy

<https://meetings.asco.org/2025-asco-annual-meeting/16345?presentation=245420#245420>

**How Much Axillary Surgery Is Necessary?**

Sunday, June 1: Education Session

10:15 – 10:30 AM

Location: E451

Presenter: Elizabeth Berger

<https://meetings.asco.org/2025-asco-annual-meeting/16438?presentation=252652#252652>

**Opting Out of Therapy for Early-Stage Breast Cancer: How Far Might We Go?**

Sunday, June 1: Education Session

10:30 – 11:00 AM

Location: E451

Panelist: Elizabeth Berger

<https://meetings.asco.org/2025-asco-annual-meeting/16438?presentation=252652#252652>

**New Drugs, New Toxicities: Side Effects of New and Emerging Breast Cancer Therapies**

Sunday, June 1: Education Session

11:30 AM – 12:45 PM

Location: E451

Panelist: Jonathan Leventhal

<https://meetings.asco.org/2025-asco-annual-meeting/16440?presentation=240860#240860>

**Skin Toxicities, Steroids, and Salves: Dermatology for Today’s Breast Cancer Oncology**

Sunday, June 1: Education Session

12:06 – 12:18 PM

Location: E451

Presenter: Jonathan Leventhal

<https://meetings.asco.org/2025-asco-annual-meeting/16440?presentation=240860#240860>

**Perturbational single-cell RNA sequencing of patient tumors in Merkel cell and small cell lung carcinomas**

Sunday, June 1: Rapid Oral Abstract

12:27 – 12:33 PM

Location: S406 | Abstract 2520

Presenter: Curtis Perry

<https://meetings.asco.org/abstracts-presentations/248723>

**Developmental Therapeutics—Immunotherapy**

Sunday, June 1: Panel Q&A

12:33 – 12:45 PM

Location: S406

Panelist: Curtis Perry

<https://meetings.asco.org/2025-asco-annual-meeting/16349?presentation=248723#248723>

**The Dr. Bernard Fisher Memorial Annual Clinical Science Symposium Supported by the Breast Cancer Research Foundation: ctDNA for Breast Cancer: It's Here—Are We Ready?**

Sunday, June 1: Clinical Science Symposium

4:30 – 6:00 PM

Location: Arie Crown Theater

Panelist: Lajos Pusztai

<https://meetings.asco.org/2025-asco-annual-meeting/16336?presentation=247723#247723>

**Circulating tumor (ct)DNA monitoring of ER+/HER2- high-risk breast cancer during adjuvant endocrine therapy**

Sunday, June 1: Clinical Science Symposium

4:54 – 5:06 PM

Location: Arie Crown Theater | Abstract 1010

Presenter: Lajos Pusztai

<https://meetings.asco.org/2025-asco-annual-meeting/16336?presentation=247723#247723>

**From Localized to Metastatic: Navigating the Renal Cell Carcinoma Treatment Landscape**

Monday, June 2: Case-Based Panel

8:00 – 9:00 AM

Location: Hall B1

Panelist and Presenter: Scott Capozza

<https://meetings.asco.org/2025-asco-annual-meeting/16504?presentation=240696#240696>

**Highlights of the Day II: Breast Cancer – Metastatic**

Monday, June 2: Special Session

8:30 – 8:45 AM

Location: Hall D1

Presenter: Maryam Lustberg

<https://meetings.asco.org/2025-asco-annual-meeting/16484?presentation=252865#252865>

**Evaluating the prognostic utility of cell-free (cf)DNA tumor fraction (TF) in metastatic castration-resistant prostate cancer (mCRPC)**

Monday, June 2: Poster Session

9:00 AM – 12:00 PM

Location: Hall A | Abstract 5052 | Poster Board 251

Presenter: Daniel Boiarsky

<https://meetings.asco.org/2025-asco-annual-meeting/16366?presentation=252890#252890>

**Investigation of tumor-associated macrophages (TAMs) and therapeutic resistance to immune checkpoint inhibitors (ICI) through single-cell analysis of renal cell carcinoma (RCC)**

Monday, June 2: Poster Session

9:00 AM – 12:00 PM

Location: Hall A | Abstract 4527 | Poster Board 372

Presenter: Soki Kashima

<https://meetings.asco.org/2025-asco-annual-meeting/16363?presentation=252966#252966>

**Prospective decision impact study of the Breast Cancer Index: Results from the BCI Registry study**

Monday, June 2: Poster Session

9:00 AM – 12:00 PM

Location: Hall A | Abstract 531 | Poster Board 124

Presenter: Tara Sanft

<https://meetings.asco.org/2025-asco-annual-meeting/16339?presentation=244520#244520>

**Assessment of time-to-treatment-failure (TTF) as a surrogate endpoint for overall survival (OS) to immune checkpoint inhibitor (ICI) regimens in metastatic renal cell carcinoma (mRCC): Findings from an IMDC analysis**

Monday, June 2: Poster Session

9:00 AM – 12:00 PM

Location: Hall A | Abstract 4528 | Poster Board 378

Presenter: Zachary Yochum

<https://meetings.asco.org/2025-asco-annual-meeting/16363?presentation=252966#252966>

**Co-expression network-based analysis of gene programs contributing to immune checkpoint inhibitor (ICI) resistance in renal cell carcinoma (RCC)**

Monday, June 2: Poster Session

9:00 AM – 12:00 PM

Location: Hall A | Abstract 4308 | Poster Board 330

Presenter: Ro Malik

<https://meetings.asco.org/2025-asco-annual-meeting/16363?presentation=252966#252966>

**Ongoing phase 1/2 trial of the hematopoietic progenitor kinase 1 (HPK1) inhibitor NDI-101150 as monotherapy or in combination with pembrolizumab: Clinical safety and efficacy update in clear cell renal cell carcinoma (ccRCC)**

Monday, June 2: Poster Session

9:00 AM – 12:00 PM

Location: Hall A | Abstract 4537 | Poster Board 337

Presenter: David Braun

<https://meetings.asco.org/2025-asco-annual-meeting/16363?presentation=252966#252966>

**Phase 2 trial of dual EGFR inhibition with cetuximab and afatinib in patients with recurrent/metastatic head and neck squamous cell cancers (HNSCC)**

Monday, June 2: Poster Session

9:00 AM – 12:00 PM

Location: Hall A | Abstract 6023 | Poster Board 431

Presenter: Aarti Bhatia

<https://meetings.asco.org/2025-asco-annual-meeting/16372?presentation=248628#248628>

**TP53 genomic alterations including targetable TP53 Y220C mutation in clinically advanced breast cancer**

Monday, June 2: Poster Session

9:00 AM – 12:00 PM

Location: Hall A | Abstract 1043 | Poster Board 22

Presenter: Nicole Casasanta

<https://meetings.asco.org/2025-asco-annual-meeting/16342?presentation=248835#248835>

**Quantifying the clinical impact of tissue reflex testing for liquid biopsy ESR1 mutation–negative cases with low ctDNA tumor fraction (TF) in HR(+)HER2(-) breast cancer**

Monday, June 2: Poster Session

9:00 AM – 12:00 PM

Location: Hall A | Abstract 1065 | Poster Board 44

Presenter: Jing Du

<https://meetings.asco.org/2025-asco-annual-meeting/16342?presentation=248835#248835>

**Clinical, sociodemographic, and facility-related determinants of immunotherapy use in metastatic triple-negative breast cancer**

Monday, June 2: Poster Session

9:00 AM – 12:00 PM

Location: Hall A | Abstract 1105 | Poster Board 84

Presenter: Ismail Ajjawi

<https://meetings.asco.org/2025-asco-annual-meeting/16342?presentation=248835#248835>

**Highlights of the Day II: Lung Cancer – Non Small Cell Metastatic**

Monday, June 2: Special Session

9:15 – 9:30 AM

Location: Hall D1

Presenter: Sarah Goldberg

<https://meetings.asco.org/2025-asco-annual-meeting/16484?presentation=252865#252865>

**ADC 2.0: Discovering the Targets That Will Change the Game**

Monday, June 2: Special Session

9:45 – 11:15 AM

Location: Hall D1

Panelist: Patricia LoRusso

<https://meetings.asco.org/2025-asco-annual-meeting/16479?presentation=252148#252148>

**Unlocking the Power of Antibody-Drug Conjugates: From Promise to Practice and Beyond**

Monday, June 2: Special Session

9:45 – 9:57 AM

Location: Hall D1

Presenter: Patricia LoRusso

<https://meetings.asco.org/2025-asco-annual-meeting/16479?presentation=252148#252148>

**A generative model for the design of novel inhibitors targeting the PD-1/PD-L1 pathway**

Monday, June 2: Poster Session

1:30 – 4:30 PM

Location: Hall A | Abstract 2576 | Poster Board 223

Presenter: Juan Velasco

<https://meetings.asco.org/2025-asco-annual-meeting/16351?presentation=246678#246678>

**Implementation of a novel interdisciplinary pharmacology curriculum in a hematology/oncology fellowship program**

Monday, June 2: Poster Session

1:30 – 4:30 PM

Location: Hall A | Abstract 9028 | Poster Board 17

##### Presenter: Tendai Kwaramba

<https://meetings.asco.org/2025-asco-annual-meeting/16389?presentation=248851#248851>

**A phase 2 study of olaparib in IDH1 and IDH2 mutant advanced chondrosarcomas and other solid tumors**

Monday, June 2: Poster Session

1:30 – 4:30 PM

Location: Hall A | Abstract 3087 | Poster Board 402

##### Presenter: Philippos Apolinario Costa

<https://meetings.asco.org/2025-asco-annual-meeting/16354?presentation=246512#246512>

**A phase 2 study of the olaparib and AZD6738, an ATM/ATR inhibitor, in isocitrate dehydrogenase (IDH) mutant solid tumors**

Monday, June 2: Poster Session

1:30 – 4:30 PM

Location: Hall A | Abstract 3089 | Poster Board 404

##### Presenter: Philippos Apolinario Costa

<https://meetings.asco.org/2025-asco-annual-meeting/16354?presentation=246512#246512>

**AI-driven design of novel PARP inhibitors**

Monday, June 2: Poster Session

1:30 – 4:30 PM

Location: Hall A | Abstract 3091| Poster Board 406

##### Presenter: Juan Velasco

<https://meetings.asco.org/2025-asco-annual-meeting/16354?presentation=246512#246512>

**Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant**

Monday, June 2: Oral Abstract

3:00 – 6:00 PM

Location: S100a

Panelist: Amer Zedian

<https://meetings.asco.org/2025-asco-annual-meeting/16374?presentation=244201#244201>

**An all-oral regimen of decitabine-cedazuridine (DEC-C) plus venetoclax (VEN) in patients (pts) with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy: Results from a phase 2 cohort of 101 pts**

Monday, June 2: Oral Abstract

4:12 – 4:24 PM

Location: S100a | Abstract 6504

Presenter: Amer Zedian

<https://meetings.asco.org/2025-asco-annual-meeting/16374?presentation=244201#244201>